Companies in the news: AG Barr & Britvic

Share

• Copy link
• Facebook
• X
• Linkedin
• Whatsapp
• Pinterest

Share this article

Join the conversation

Follow us

Add us as a preferred source on Google

Newsletter

Get the MoneyWeek Newsletter

Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.

Contact me with news and offers from other Future brands Receive email from us on behalf of our trusted partners or sponsors

---

By submitting your information you agree to the Terms & Conditions and Privacy Policy and are aged 16 or over.

You are now subscribed

Your newsletter sign-up was successful

---

Want to add more newsletters?

Twice daily

MoneyWeek

Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.

Signup +

Four times a week

Look After My Bills

Sign up to our free money-saving newsletter, filled with the latest news and expert advice to help you find the best tips and deals for managing your bills. Start saving today!

Signup +

---

An account already exists for this email address, please log in.

Subscribe to our newsletter

Drinks groups AG Barr (LSE: BAG)and Britvic (LSE: BVIC)will not be getting together.

This is a shame for Barr's shareholders, as its management could have made a great success of Britvic and struck a great price. A Competition Commission enquiry cleared the deal, but it has taken too long: a change of leader at Britvic has seen the firm move on on its own.

This leaves Barr shares trading on over 20 times forecast earnings, with the bottom line growing at around 10% next year. Without a transformational deal, this is too high.

MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up

There is talk of Barr bidding for GlaxoSmithKline's Ribena and Lucozade brands, but the asking price is likely to be steep due to lots of interest. The shares have gained 16% since I tipped them last October. I like this business, but it's time to take profits.

Britvic shares are up 14% since I tipped them in April and are cheaper on 16 times earnings. Cost cutting should drive profits for the next year or so, but it has to prove it can grow its sales consistently. They also look less attractive without a Barr tie-up. Take profits here too.

Verdict: take profits on both Barr and Britvic